XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative Arrangements (Tables)
 6 Months Ended
Jun. 30, 2024
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2024202320242023
Alliance revenue - Lynparza$317 $310 $609 $585 
Alliance revenue - Koselugo37 25 75 48 
Total alliance revenue$354 $335 $684 $633 
Cost of sales (1)
82 78 163 148 
Selling, general and administrative43 51 82 98 
Research and development18 22 38 43 
($ in millions)June 30, 2024December 31, 2023
Receivables from AstraZeneca included in Other current assets
$349 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
615 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
— 600 
(1)    Represents amortization of capitalized milestone payments.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2024202320242023
Alliance revenue - Lenvima$249 $242 $504 $474 
Cost of sales (1)
60 57 121 183 
Selling, general and administrative41 48 80 99 
Research and development6 17 13 56 
($ in millions)June 30, 2024December 31, 2023
Receivables from Eisai included in Other current assets
$245 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
— 125 
(1)    Represents amortization of capitalized milestone payments. Amount in the first six months of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2024202320242023
Alliance revenue - Adempas/Verquvo$106 $68 $203 $167 
Net sales of Adempas recorded by Merck72 65 142 125 
Net sales of Verquvo recorded by Merck9 9 16 16 
Total sales$187 $142 $361 $308 
Cost of sales (1)
61 56 123 113 
Selling, general and administrative26 34 59 67 
Research and development28 25 55 50 
($ in millions)June 30, 2024December 31, 2023
Receivables from Bayer included in Other current assets
$170 $156 
Payables to Bayer included in Accrued and other current liabilities
81 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2024202320242023
Net sales of Lagevrio recorded by Merck
$110 $203 $460 $595 
Cost of sales (1)
96 193 287 414 
Selling, general and administrative
16 24 32 51 
Research and development
7 10 2 26 
($ in millions)June 30, 2024December 31, 2023
Receivables from Ridgeback included in Other current assets
$8 $— 
Payables to Ridgeback included in Accrued and other current liabilities (2)
24113
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2024202320242023
Selling, general and administrative $14 $— $16 $— 
Research and development
65 — 133 — 
($ in millions)June 30, 2024December 31, 2023
Payables to Daiichi Sankyo included in Accrued and other current liabilities
$801 $800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities
750 750 
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2024202320242023
Selling, general and administrative $4 $1 $6 $2 
Research and development
93 60 162 86 
($ in millions)June 30, 2024December 31, 2023
Payables to Moderna included in Accrued and other current liabilities
$73 $63